베타카로틴강화미에 삽입된 발현단백질 PAT, 2A, CtrI, PSY의 안전성평가의 일환으로 항원성시험을 실시하였다. 그 결과, 발현단백질 PAT 고농도 투여군에서 총백혈구함량이 높게 측정되었나, 다른 발현단백질 간에는 큰 차이를 나타내지 않았다. 아나필락시스쇼크반응에서는 발현단백질 PAT 고농도 투여군에서 경미한 또는 중등정도의 증상이 나타냈으나 사망 개체는 없었다. 수동아나필락시스반응시험결과, 발현단백질 PAT, 2A, PSY 및 혼합 고농도투여군의 낮은 항혈청농도에서 양성반응이 나타났고, 혼합 임상농도 투여군에서는 경미한 양성반응을 보였다. 그러나, 발현단백질 PAT, 2A, PSY, CtrI 임상농도 투여군에서는 양성반응을 보이지 않아 IgE를 생성하지 않는 것으로 판단되며, 베타카로틴강화미의 안전성 입증을 위해 더 다양한 연구가 필요하다고 사료된다.
As part of safety evaluation of 2A (amono acid), PAT (phosphinotricin Acetyl-transferase), CtrI (Carotene desaturase) and PSY (phytoene synthase), the expressed proteins inserted to ${eta}$-carotene Biofortified rice were tested for antigencity test. As a result, the group of administering high-concentration PAT, the expressed protein, showed a great content of total WBC; however, other expressed proteins did not show much difference. Against ASA (Active Systemic Anaphylaxis) test, the group of administering high-concentration PAT, the expressed protein, showed mild or medium degree of symptoms, but there was no dead entity. According to the result of the PCA (Passive Cutaneous Anaphylaxis test), the group of administering high-concentration PAT, 2A, PSY, and mixture of expressed proteins indicated positive response in low anti-serum concentration, and the group of administering the clinical concentration of mixture indicated mild positive response. However, because the group of administering the clinical concentration of expressed proteins, PAT, 2A, PSY, and CtrI, did not show positive response, it is thought that IgE is not generated. Further studies are needed to verify the safety of ${eta}$-carotene Biofortified rice.
